There are currently 967 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
NCT03554356
Recruiting
A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or \<50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
Register for Updates
Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906
NCT04717934
Recruiting
Main study: Randomized, evaluator-blinded, no treatment controlled multicenter study to evaluate safety and effectiveness of GAL1906 for the correction of wrinkles in the décolletage area. Sub-study: To evaluate imaging interpretation of mammograms in subjects who were enrolled and treated in the 43USRV1906 main study. The sub-study will determine if hyaluronic acid injections in the décolletage interfere with diagnosis or interpretation of mammogram results.
Gender:
FEMALE
Ages:
22 years and above
Trial Updated:
02/11/2025
Locations: Galderma Research Site, Birmingham, Alabama
Conditions: Wrinkle
Register for Updates
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day
NCT06436924
Recruiting
SAFE HV is an observational, prospective, multi-center, non-randomized study evaluating real-world clinical experience of centers where a single procedural physician schedules eight or more left atrial appendage occlusion (LAAO) device implant procedures in a single calendar day.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Grandview Medical Center, Birmingham, Alabama
Conditions: Atrial Fibrillation
Register for Updates
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
Recruiting
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
02/11/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
Register for Updates
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
NCT06639958
Recruiting
This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home. One problem with ALL maintenance treatment is remembering to take medicines at home like patients are supposed to. In maintenance, a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home. In this study, 6MP prescriptions are filled into a special medication bottle called MEMS® which is fitted with a sp... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
02/11/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Register for Updates
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
NCT06247787
Recruiting
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
02/11/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Recurrent Juvenile Myelomonocytic Leukemia, Refractory Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome
Register for Updates
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905
Recruiting
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/11/2025
Locations: Clinical Trial Site, Birmingham, Alabama
Conditions: Acute Hepatic Porphyria
Register for Updates
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
NCT03901807
Recruiting
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Septic Shock, Endotoxemia
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
A Study of BION-1301 in Adults With IgA Nephropathy
NCT05852938
Recruiting
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama
Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Register for Updates